Lilly strikes second partnership this year for recombinase-based gene editing

Ali Madani, Profluent CEO (Carlos Rodrigues/Sportsfile for Web Summit via Getty Images) April 28, 2026 07:00 AM EDT DealsCell/Gene Tx Lil­ly strikes sec­ond part­ner­ship this year for re­com­bi­nase-based gene edit­ing Ryan Cross Senior Science Correspondent Decades be­fore CRISPR gene edit­ing was in­vent­ed, sci­en­tists tried to ma­nip­u­late genes with en­zymes called re­com­bi­nas­es. The pro­teins were pre­cise but proved tricky to use … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER